Cordlife launches newborn metabolic screening service in Hong Kong

Cordlife launches newborn metabolic screening service in Hong Kong

Michelle Zhu
02/05/18, 01:14 pm

SINGAPORE (May 2): HealthBaby Biotech (Hong Kong), a wholly-owned subsidiary of Cordlife Group, has launched a newborn metabolic screening service in Hong Kong.

This comes as part of Cordlife’s move to expand its diagnostics business, says the group in a press release issued on Wednesday.

Named Metascreen, the service uses urine instead of blood to detect over 100 inherited metabolic disorders – which is much more than what can be detected by conventional newborn metabolic screening tests currently available in Hong Kong, according to the group.

The specimens are taken from babies 48 hours after birth and up to six months old, and will be testing using an US-FDA-approved Gas Chromatography/Mass Spectrometry platform from Japan at the laboratory of Hong Kong Screening Centre, which is another subsidiary of Cordlife.

Aside from Metascreen being a non-invasive procedure, Cordlife emphasises that using urine as a test specimen is highly effective as metabolites tend to accumulate in urine first, while blood accumulation of toxic substances will only appear once the kidney clearance capacity is exceeded.

The group also says that Metascreen can provide “highly specific and definite results” as it analyses up to four analyte profiles to detect a single metabolic disorder – which helps to reduce false positive rates compared to conventional newborn metabolic screening, which usually only uses one or two analyte profiles in comparison.

“The launch of Metascreen by HealthBaby enables us to reach an even wider audience in Hong Kong. This will give more parents the opportunity to take proactive steps in enabling early detection, which can help avoid lifelong and potentially fatal effects of inborn errors of metabolism,” said Michael Weiss, Group CEO and Executive Director of Cordlife.

“New Cordlife is all about leveraging our extensive, multi-national platform to access large pockets of demand for all new offerings. We will continue to add innovative new services that can, to the greatest extent possible, be ‘plugged in and played’ across the entire system,” he adds.

As at 1.15pm, shares in Cordlife are trading flat at 70 cents.

Right timing: STI stays intact, but Hong Fok is at extreme overbought high

SINGAPORE (Mar 23): Although quarterly momentum appears ambivalent as it is consolidating beneath its own moving average, prices are intact. They have established support at the confluence of the 50- and 200-day moving averages which are moving into an increasingly positive stance at 3,217 and 3,186 respectively. The index may well be able to regain its 50-day moving average as short term stochastics is turning up from the bottom of its range. Since medium term indicators are neutral and drifting sideways, short term indicators could keep the STI afloat. However the range is likely to be ....

EY Singapore launches 18th edition of Entrepreneur Of The Year awards

SINGAPORE (Mar 22): The search has started for the 18th EY Entrepreneur Of The Year, as part of the bid to promote entrepreneurship and shape a new role model for the business community. Ernst & Young LLP, organiser of the annual awards, observes that entrepreneurs in Singapore, and the world, have built some of the world’s most enduring companies. The businesses they build don’t just create employment and contribute to the GDP. “Their creativity, tenacity and courage serve as an inspiration for many. In many ways, the way they overcome the odds, the power of their influence, a....

Challenger Tech's 2.94% shareholder says offer price too low, calls for higher dividend payouts

SINGAPORE (Mar 22): Pangolin Investment Management, which holds a 2.94% stake in Challenger Technologies through its Pangolin Asia Fund, is calling on other shareholders to reject Digileap Capital’s delisting offer at the company’s upcoming EGM.   Pangolin says the offer price of 56 cents per share, which translates to a price-to-earnings ratio of 9.9 times, is too low and thus unfair to minority shareholders. In a letter sent to The Edge Singapore on Friday, Pangolin explains its reasons for strongly advising other Challenger shareholders to reject the offer, which it deems “....